Wesley R. Zemrak

Wesley R. Zemrak

Auto-generated profile, based on publicly available information

Wesley R. Zemrak

Maine Medical Center, Portland, ME, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2020 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
RRRichard R. Riker
Richard R. Riker
TMTeresa L. May
Teresa L. May
GFGilles L. Fraser
Gilles L. Fraser
DGDavid J. Gagnon
David J. Gagnon
MBMahesh Bandara
Mahesh Bandara
DSDavid B. Seder
David B. Seder
Early reports of COVID‐19 clinical features describe a hypercoagulable state, and recent guidelines recommend prophylactic anticoagulation for COVID‐19 patients with low molecular weight heparin, but this would be contraindicated in the presence of heparin‐induced thrombocytopenia (HIT). We address the key clinical question whether HIT is also present during COVID‐19. We report 3 cases of thrombocytopenia with anti‐platelet factor 4 antibodies among 16 intubated COVID‐19 patients with adult respiratory distress syndrome, a higher than expected incidence of 19%. Each patient had evidence of thrombosis (pulmonary embolism, upper extremity venous thromboses, and skin necrosis, respectively). The serotonin release assay confirmed HIT in one case, and two cases were negative. We believe this is the first reported case of HIT during the COVID‐19 pandemic. Recognition that the thrombocytopenia represented HIT in the confirmed case was delayed. We recommend clinicians monitor platelet counts closely during heparin therapy, with a low threshold to evaluate for HIT.

1 August 2016 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
WZWesley R. Zemrak
Wesley R. Zemrak
EKErin Kelley
Erin Kelley
NKNicole L. Kovacic
Nicole L. Kovacic
DMDeirdre M. Mooney
Deirdre M. Mooney
JMJane G. Morris
Jane G. Morris
JRJeffrey A. Rosenblatt
Jeffrey A. Rosenblatt

28 June 2017 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
WZWesley R. Zemrak
Wesley R. Zemrak
KSKathryn E. Smith
Kathryn E. Smith
SRStephen S. Rolfe
Stephen S. Rolfe
TMTeresa May
Teresa May
RTRobert L. Trowbridge
Robert L. Trowbridge
DSDavid B. Seder
David B. Seder

15 November 2018 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
WZWesley Zemrak
Wesley Zemrak
FMFrancis Manuel
Francis Manuel
KSKathryn E. Smith
Kathryn E. Smith
SRStephen Rolfe
Stephen Rolfe
THTimothy Hayes
Timothy Hayes
DSDavid Seder
David Seder

1 July 2021 in Mental Health Clinician
Verified
Journal Article
Open access
PDF file
NCNicolette R. Centanni
Nicolette R. Centanni
WCWendy Y. Craig
Wendy Y. Craig
DWDena L. Whitesell
Dena L. Whitesell
WZWesley R. Zemrak
Wesley R. Zemrak
SNStephanie D. Nichols
Stephanie D. Nichols
Introduction: This study assessed the use, tolerability, and safety of anticoagulation via direct oral anticoagulants or warfarin in medical and psychiatric inpatients receiving ECT. Methods: This retrospective cohort study included 32 patients who received ECT while on either a direct oral anticoagulant (9) or warfarin (23) and spanned 247 encounters at Maine Medical Center between December 2012 and December 2018. Data are presented descriptively and analyzed using SPSS version 25 and Microsoft Excel version 2016. Results: Among the 247 ECT patient encounters, there were few major adverse effects of ECT in this medically complex population. These adverse effects included headache during 4 encounters (1.6%), respiratory distress during 2 encounters (0.8%) and a cardiovascular event during 1 encounter (0.4%). One patient (3.1%) who was receiving concurrent rivaroxaban and venlafaxine experienced gastrointestinal bleeding that was determined to be unrelated to ECT. One patient on fluoxetine and warfarin experienced hemoptysis thought to be secondary to epistaxis. No other major bleeding or clotting event occurred during an ECT session nor for the duration of the hospitalization. Discussion: Direct oral anticoagulants and warfarin appear safe in the treatment of patients with atrial fibrillation or acute venous thromboembolism who are receiving concomitant ECT. Prospective studies are needed to confirm these findings.

5 August 2016 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
ARAmber R. Rollins
Amber R. Rollins
KSKathryn E. Smith
Kathryn E. Smith
WZWesley R. Zemrak
Wesley R. Zemrak
Background: Transition from bivalirudin to long-term warfarin therapy is often difficult to execute due to bivalirudin prolongation of the international normalized ratio (INR), and literature to help guide this transition is extremely limited. Objective: To assess the transition from bivalirudin to warfarin after implementation of an institution-wide transition protocol. Methods: In this retrospective quasiexperimental study, adult patients receiving bivalirudin directly followed by warfarin for nonprocedural systemic anticoagulation were evaluated to determine the frequency of successful transition to warfarin. Participants were compared before (preprotocol) and after (postprotocol) the implementation of the transition protocol. Results: A total of 39 patients met inclusion criteria and were included in the analysis (preprotocol = 19; postprotocol = 20). The percentage of patients achieving a successful transition was significantly higher in the postprotocol group compared with the preprotocol group (80.0% vs 42.1%, P = 0.015). Bleeding events were similar between the 2 groups (23.1% vs 16.7%, P = 0.689). Withholding of warfarin doses or the use of anticoagulant reversal agents or blood transfusions for supratherapeutic INR levels, surgical procedures, or drop in hemoglobin was numerically lower in the postprotocol group compared with the preprotocol group (16.7% vs 46.2%, P = 0.202). Conclusion: Implementation of a simplistic bivalirudin-warfarin transition protocol significantly increased the frequency of therapeutic INR results on bivalirudin discontinuation. Additionally, patients treated according to this protocol were less likely to have warfarin doses withheld or require reversal agents. Larger studies testing this transition strategy are warranted.